Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyraâs lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and SjĂśgren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.
Source
